Managed care pharmacists are involved formally with the interface between the delivery and financing of health care; their work thus entails an accountability for both elements. Interpreted broadly, managed care pharmacists are pharmacists working within the sphere of a health care system, health care purchaser, health insurer, managed care organization, or benefit administration agency. Patients, the pharmacy profession, and society are best served by this broad interpretation, because the interdependency of financing and delivery is inextricably linked to the achievement of good health outcomes. This continuing feature will explore contemporary issues facing managed care pharmacists.
Get full access to this article
View all access options for this article.
References
1.
GoldsteinD.B.Pharmacogenetics in the laboratory and the clinic. N Engl J Med.2003; 348: 553–556.
2.
MoldrupC.When genetics goes public. N Genet Soc.2002; 21: 29–37.
3.
MeyerU.A.Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet.2004; 5: 669–676.
EvansW.E., McCleodH.L.Drug disposition, drug targets, and side effects. N Engl J Med.2003; 348: 538–549.
6.
WeinshilboumR.Inheritance and drug response. N Engl J Med.2003; 348: 529–537.
7.
CavallariL.H., ShordS.S.Pharmacogenomics. In: SchumockG.T., ed. Pharmacotherapy Self-Assessment Program. Vol 5. 5th ed.Kansas City, MO: American College of Clinical Pharmacy; 2005; 189–214.
8.
PiperM.A.Special Report: Genotyping for Cytochrome P450 Polymorphisms to Determine Drug-Metabolizer Status.Chicago, IL: Blue Cross Blue Shield Association; 2004.
PietrasR.J., FendlyB.M., ChazinV.R., PegramM.D., HowellS.B., SlamonD.J.Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene.1994; 9: 1829–1838.
11.
TeagardenJ.R.Perspectives on prescription drug benefit formularies. Hosp Pharm.2004; 39: 1102–1105.
12.
TeagardenJ.R.The effect of pharmacy benefit manager clinical programs and services on access to prescription drug benefit coverage. Drug Infor J.1998; 32: 373–377.
13.
StraderD.B., WrightT., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C. Hepatology.2004; 39: 1147–1171.
14.
TeagardenJ.R.Prior authorization in prescription drug benefit management: an apologia. Hosp Pharm.2004; 39: 493–498.
15.
ZinehI., GerhardT., AquilanteC., BeitelsheesA.L., BeasleyB.N., HartzemaA.G.Availability of pharmacogenomics based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J.2004; 4: 354–358.
16.
JohnsonJ.A., BootmanJ.L., EvansW.E.. Pharmacogenomics: A scientific revolution in pharmaceutical sciences and pharmacy practice, report of the 2001-2002 Academic Affairs Committee. Am J Pharm Educ.2002; 66: 12S–15S.
